濮陽惠成(300481.SZ):擬使用部分募集資金向福建惠成增資 用於實施相關募投項目
格隆匯6月7日丨濮陽惠成(300481.SZ)公佈,公司於2021 年6月7日召開第四屆董事會第十三次會議,審議通過了《關於公司使用部分募集資金向全資子公司增資的議案》,同意公司使用募集資金56889.88萬元及其利息(具體金額以結算時為準)向全資子公司福建惠成新材料有限公司(“福建惠成”)增資,用於實施公司向特定對象發行股票募集資金投資項目“順酐酸酐衍生物、功能材料中間體及研發中心項目”的建設。
上述增資款項中的49000萬元用於增加福建惠成註冊資本,其餘部分計入資本公積。增資完成後,福建惠成的註冊資本為50000萬元,公司仍持有其100%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.